# Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

> **NCT07625527** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Bladder (Urothelial, Transitional Cell) Cancer
- Non Muscle Invasive Bladder Cancer

## Interventions

- **BEHAVIORAL:** Active Surveillance
- **DRUG:** PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy

## Key facts

- **NCT ID:** NCT07625527
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2029-03-30
- **Final completion:** 2032-05-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625527, "Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*